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Summary Four monoclonal antibodies (MAbs) specific for the extracellular domain of the human erbB-2/
HER2 protein (FRP5, FSP16, FWP51 and FSP77) have been isolated (Harwerth et al., J. Biol. Chem., 267,
15160-15167, 1992). In this paper we describe the effects of erbB-2 specific MAb administration on the
tumorigenic growth of human erbB-2 transformed NIH3T3 cells implanted into athymic nude mice. Two
antibodies, FWP51 and FSP77, inhibited the onset of tumour growth, while the administration of FRP5 and
FSP16 did not affect tumour growth. In addition, administration of MAbs FWP51 and FSP77 led to a
retardation in the growth of established tumours. Treatment was not curative in that tumours regrew within
two weeks of the final treatment. The administration of a combination of MAbs FWP51 and FSP77 which
react with two distinct regions on the erbB-2 molecule was more effective than treatment with either MAb
alone. The two growth-inhibitory antibodies were also effective in the treatment of tumours established from
SKOV3 cells, a human ovarian tumour cell line with high levels of the erbB-2 protein. The effect of the MAbs
on the anchorage-independent growth of erbB-2 transformed cells and on erbB-2 receptor turnover was also
measured.
The erbB-2 protein is a member of the receptor tyrosine
kinase family and is closely related to the epidermal growth
factor (EGF) receptor (Schechter et al., 1984; Coussens et al.,
1985; Yamamoto et al., 1986). The oncogenic potential of the
erbB-2 receptor has been shown to be released through
different mechanisms involving point mutation (Segatto et
al., 1988; Suda et al., 1990) and overexpression. Amplifi-
cation of the c-erbB-2 gene, leading to overexpression of the
protein, has been observed in a high percentage of human
breast and ovarian tumour cells (Slamon et al., 1987; Kraus
et al., 1987; van de Vijver et al., 1987; Slamon et al., 1989). It
is likely that the elevated levels of the erbB-2 protein con-
tribute to the malignancy process. Overexpression of erbB-2
in cultured cells has been found to induce the malignant
phenotype in fibroblasts (Di Fiore et al., 1987) as well as in
mammary epithelial cells (Pierce et al., 1991). Overexpression
of erbB-2 in breast and ovarian carcinomas has been cor-
related with an unfavourable patient prognosis (Slamon et
al., 1987; Varley et al., 1987; Berger et al., 1988; Slamon et
al., 1989; Wright et al., 1989).
The use of monoclonal antibodies (MAbs) in diagnosis and
treatment of cancer has many promising aspects. The tumour
enriched expression and extracellular accessibility of the
erbB-2 receptor make it a potential target for immuno-
therapy. We have recently described several MAbs which
bind to the extracellular domain of the human erbB-2 protein
(Harwerth et al., 1992). These MAbs are able to affect erbB-
2 receptor phosphorylation and turnover, as well as the
anchorage-dependent growth properties of erbB-2-expressing
tumour cells. In this paper we describe the effect of these
anti-erbB-2 monoclonal antibodies, alone and in combina-
tion, on the tumorigenic growth of erbB-2 expressing cells in
athymic nude mice. Two of the MAbs, FWP51 and FSP77,
inhibited the onset of tumour growth. The combination of
both MAbs was more effective than individual antibody
treatment. To correlate the in vivo anti-tumour activity of the
antibodies with in vitro characteristics, individual antibodies
and antibody combinations were tested in three assays:
Anchorage-independent growth of erbB-2 transformed cells,
erbB-2 receptor tyrosine phosphorylation and receptor turn-
over following antibody treatment were measured. The
results suggest that no individual parameter correlates com-
pletely with the anti-tumour activity of a MAb. In general,
MAb induced reduction of the erbB-2 receptor level reflects
best the in vivo anti-tumour activity.
Materials and methods
Cell lines, cell culture and transfection ofNIH3T3 cells
SKBR3 and SKOV3 are human breast and ovarian tumour
cell lines, respectively, which exhibit overexpression of the
erbB-2 protein due to erbB-2 gene amplification (Hynes et al.,
1989; Marth et al., 1990). Clone NIH3T3#3.7 is a mouse
fibroblast cell line stably transfected with a plasmid express-
ing the activated human c-erbB-2 gene under control of the
SV40 promoter (pSV2erbB-2(VE)) (Masuko et al., 1989) and
pSV2neo, which confers resistance to the antibiotic G418
sulfate.
All cell lines were maintained in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% foetal calf
serum (FCS). In addition medium for the NIH3T3#3.7 cell
line contained 600 lagml-' of G418 sulfate.
Experimental animals
Ten to twelve week old athymic female Balb/c nude (nu/nu)
mice were obtained from Bomholtgaard, Kopenhagen, Den-
mark. The animals were maintained under sterile conditions,
65% humidity, 25'C and with food and water ad libitum.
Monoclonal antibodies
Four monoclonal antibodies (FRP5, FSP16, FWP51, FSP77)
which specifically bind the extracellular domain of the human
erbB-2 receptor were isolated and characterised as described
(Harwerth et al., 1992). Their binding affinities were deter-
mined by ELISA as described (Wels et al., 1992a).
Tumour cell implantation and measurement of tumour growth
NIH3T3#3.7 cells (approximately 5 x 106/mouse) were s.c.
injected into the flanks of athymic nude mice. On the same
day and on nine ensuing days the individual MAbs or com-
binations of two MAbs were i.v. injected. During the 10 days
groups of five mice received a total of 0.5 mg MAb/mouse or
0.25 mg FWP51 + 0.25 mg FSP77/mouse in the case of the
combination treatment.
In a parallel experiment the antitumour activity of a single-
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chain antibody-exotoxin A recombinant protein,
scFv(FRP5)-ETA, was tested. The construction and expres-
sion of a gene encoding the chimeric protein and its
purification and biological activity have been described
previously (Wels et al., 1992b). Mice received s.c. injections
of approximately 5 x 106cells. The same day Alzet
minipumps (model 2001) containing scFv(FRP5)-ETA in
200 jli PBS or 200jl PBS alone were s.c. implanted into two
groups of five animals. The pumps continuously delivered
material for approximately 7 days and the treated animals
received a dose of 6jig of scFv(FRP5)-ETA/day.
An athymic mouse model of the human ovarian tumour
cell line SKOV3 was also tested. Approximately 25 mg of
SKOV3 tumour tissue was s.c. implanted into three groups of
five mice. Therapy was initiated 5 days post implantation
when tumours had reached approximately 50 mm3 and was
carried out for 10 days. The animals received a total amount
of 0.5 mg of MAb FWP51 or MAb FSP77/mouse or PBS.
Tumour growth was followed by measuring two perpen-
dicular tumour diameters, the tumour volumes were cal-
culated, and the data were statistically analysed as described
(Meyer et al., 1989).
Anchorage-independent growth assay
Anchorage-independent growth was studied by examining the
colony-forming capability of NIH3T3#3.7 cells suspended in
soft-agar. Experiments were performed using 35 mm tissue
culture dishes. A 1 ml cell-free feeder layer consisted of 0.8%
agarose-DMEM supplemented with 6% FCS. The 1 ml over-
layer contained 1 x 103 cells in 0.3% agarose-DMEM supp-
lemented with 5% FCS and the MAbs (10 igml-'), which
were only added to the top layer. To stain colonies 1 ml of
PBS containing 0.5 mg ml-' nitro blue tetrazolium (Sigma)
was added to the cultures on day 20. The next day colonies
) 0.2 mm were counted using an Artek Counter (Dynatech
Laboratories, Inc.). The results from each experimental
group represent the mean of triplicate samples.
Determination ofthe effect ofthe monoclonal antibodies on
receptor turnover (downregulation assay)
Subconfluent cultures of NIH3T3#3.7, SKOV3 and SKBR3
cells were metabolically labelled for 16 h in methionine-free
DMEM containing 2% dialysed FCS and 50pCi ml-' of
[35S] methionine (Trans35Slabel, ICN Radiochemicals). Cells
were chased with fresh medium in the absence or presence of
10jg ml-' of monoclonal antibodies for 3 h or 24 h and
were extracted in lysis buffer as described previously
(Harwerth et al., 1992). The erbB-2 protein was immuno-
precipitated from aliquots oflysate containing equal amounts
of [35S] using the 21N antiserum (Hynes et al., 1989). A
mixture of the four erbB-2 specific monoclonal antibodies
was used in order to immunoprecipitate only the transfected
human erbB-2 protein from the NIH3T3#3.7 cell extracts.
The gels were run and the bands quantitated as de-
scribed.
tutively phosphorylated in both cases (Peles et al., 1991).
Thus, activation of erbB-2 by a point mutation should reflect
the situation of human tumours overexpressing this recep-
tor.
Following s.c. injection of NIH3T3#3.7 cells into athymic
nude mice, rapidly growing tumours are formed with a short
latency. Individual MAbs were i.v. injected into groups of
five mice, on days 0 to 9 after s.c. inoculation of approx-
imately 5 x 106 NIH3T3#3.7 cells. Figure 1 shows that the
tumorigenic growth of NIH3T3#3.7 cells was significantly
inhibited in nude mice injected with MAbs FWP51 and
FSP77, when compared with control mice. Total inhibition
was achieved during the period of MAb-treatment and the
inhibitory effect persisted up to 12 days following the final
injection. Afterwards the tumours began to grow rapidly.
Thus treatment with the erbB-2 specific MAbs FWP51 and
FSP77 significantly delayed the onset of tumour growth, but
was not curative. In two separate experiments, MAb FSP77
was found to be more potent in tumour growth inhibi-
tion.
The two growth inhibitory MAbs recognise two distinct
domains on the erbB-2 molecule as determined by competi-
tion experiments described previously (Harwerth et al., 1992).
The effect of treating tumour-bearing animals with a com-
bination of FWP51 and FSP77 was examined. Figure 1
demonstrates that the combinatorial treatment was more
effective than single antibody treatment. The tumours started
to grow 15 days after the last MAb-injection.
Treatment of animals with MAbs FRP5 and FSP16 which
compete with each other for erbB-2 binding (Harwerth et al.,
1992) had no effect on the tumour growth of NIH3T3#3.7
cells (Figure 2a). The lack of effect is not due to a trivial
reason such as low affinity since the binding constants of all
four MAbs are comparable (Table I). In addition the isotype
of FRP5 is the same as that of the growth inhibitory
antibodies FWP51 and FSP77. MAbs FRP5 and FSP16 bind
to a domain distinct from those recognised by MAbs FWP51
and FSP77. It is likely that antibody binding to different
domains on the erbB-2 receptor can influence in vivo tumour
growth.
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The effects ofthe erbB-2 specific monoclonal antibodies upon
tumour growth
Four monoclonal antibodies (FRP5, FSP16, FWP51 and
FSP77), which specifically recognise the extracellular domain
of the human erbB-2 receptor have recently been isolated and
characterised (Harwerth et al., 1992). The in vivo anti-tumour
activity of the erbB-2 specific MAbs was tested in two
models. The first model consists of NIH3T3 transfectants
(NIH3T3#3.7) expressing an activated erbB-2 receptor, the
second model is a human ovarian carcinoma cell line
(SKOV3) with high levels of the normal erbB-2 protein.
Activation of the erbB-2 receptor by a point mutation or by
overexpression is comparable in that the receptor is consti-
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Figure 1 Effect of treatment with MAbs FWP51, FSP77 and a
combination of both on NIH3T3#3.7 cells grown as tumours in
athymic nude mice. NIH3T3#3.7 cells were s.c. injected into four
groups of five nude mice. Mice received PBS or 50fig of the
individual MAbs or 25jig FWP51 + 25 lag FSP77 as a
combination/mouse/day during a period of 10 days. Tumour sizes
were measured at the indicated times, tumour volumes were
calculated, and the data were statistically analysed.1142 I.-M. HARWERTH et al.
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Figure 2 Effect of MAbs and scFv(FRP5)-ETA on
NIH3T3#3.7 tumour cell growth in athymic mice. (a)
NIH3T3#3.7 cells were s.c. injected into three groups of five
nude mice. Monoclonal antibodies (50Jg/day/mouse) or PBS
were injected starting on day 0 and treatment continued until day
9. (b) NIH3T3#3.7 cells were s.c. injected into two groups of five
nude mice. Mice were treated by s.c. implantation of pumps
which continuously released scFv(FRP5)-ETA for 7 days at a
rate of 6 tg/day/mouse. The pumps for the control group con-
tained PBS. Tumour growth was determined as in Figure 1.
Table I
Isotype and
Mab subclass KD 10-Ma
FRP5 IgG1, k 0.82
FSP16 IgG2b, k 0.98
FWP51 IgG1, k 1.3
FSP77 IgG1, k 0.38
aThe affinities were determined by ELISA as described in
Materials and methods and ref. Wels et al., 1992a and were
measured as the half-maximal saturation value.
It is possible to develop a cytotoxic reagent using MAb
FRP5. We have recently described the isolation and charac-
terisation of a recombinant single chain antibody-exotoxin A
fusion protein, scFv(FRP5)-ETA. The antigen-binding
domain of MAb FRP5 was fused to a truncated Pseudo-
monas exotoxin A. The scFv(FRP5)-ETA molecule inhibited
the growth of human tumour xenografts in nude mice (Wels
et al., 1992b). Figure 2b shows the in vivo antitumour activity
of the recombinant scFv(FRP5)-ETA molecule on
NIH3T3#3.7 cells. 2 x 106 tumour cells were inoculated in
nude mice on day 0. On the same day miniosmotic pumps
which continuously delivered scFv(FRP5)-ETA at a rate of
61g/day were s.c. implanted into a group of five mice. The
pumps delivered a constant amount of material for approxi-
mately 7 days. In the group that received the recombinant
scFv(FRP5)-ETA there was minimal tumour growth up to
day 21. In contrast to the treatment with MAb FRP5 which
exhibited no effect on the onset of tumour growth, tumour
growth was inhibited by 80% in animals which received
6 ,ug/day of scFv(FRP5)-ETA.
To examine the effect of the monoclonal antibodies on the
tumorigenic growth of human cancer cells, SKOV3 ovarian
tumour cells which express high levels of the erbB-2 protein
were studied. The carcinoma cells grow as xenografts in nude
mice and approximately 25 mg of SKOV3 tumour tissue were
s.c. implanted into the flanks of three groups of five mice.
The implants grew for 5 days to a size of approximately
50 mm3 and antibody treatment was begun by i.v. injection
of 50 Lg/mouse/day of MAbs FWP51 or FSP77. Figure 3
demonstrates that during the 10 day treatment period MAbs
FWP51 and FSP77 almost completely inhibited tumour
growth. Once treatment was discontinued, tumour growth
started 2-4 days later. The delay was slightly longer in
animals which had received MAb FWP51.
The effects ofthe erbB-2 specific MAbs on the
anchorage-independent growth oferbB-2 transformed cells
We examined the effect of the erbB-2 specific antibodies and
of the combination of FWP51 + FSP77 on the anchorage-
independent growth of NIH3T3#3.7 cells. As depicted in
Figure 4 the four MAbs had distinct effects on soft-agar
colony formation. Of the two MAbs which showed in vivo
inhibitory effects, only MAb FWP51 inhibited colony forma-
tion while MAb FSP77 was moderately stimulatory at the
lowest dose tested (5-fold at 10 pg). MAbs FRP5 and FSP16,
which did not have any significant effect on tumour growth,
exerted a marked stimulatory effect on NIH3T3#3.7 cells.
An 8 to 11 fold increase in the number of soft-agar colonies
was observed. The effects of the MAbs on NIH3T3#3.7
soft-agar colony formation were dose dependent. MAbs
FRP5, FSP16 and FSP77 were most stimulatory at low
doses. MAb FWP51 inhibited colony formation best at high
doses (85% at 501gml--'). A control IgG-antibody did not
affect colony formation (data not shown). Another control
showed that there was no stimulatory effect on anchorage-
independent growth of pSV2neo expressing NIH3T3 fibro-
blasts following treatment with the erbB-2 specific MAbs
(data not shown). Therefore, the effects of the antibody
treatment are dependent upon the expression of the human
erbB-2 receptor.
The effect ofthe monoclonal antibodies on the rate ofreceptor
turnover
The interaction of receptor tyrosine kinases with their ligands
is coupled to rapid endocytosis. Monoclonal antibodies can
induce an analogous effect on the rat neu receptor (Drebin et
al., 1985; Yarden, 1990) and on the human erbB-2 receptor
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Figure 3 Effect of MAbs FWP51 and FSP77 on the growth of
SKOV3 human ovarian tumour xenografts in athymic mice. Ap-
proximately 25 mg of SKOV3 tumour tissue were s.c. implanted
into three groups of five nbde mice. Five days later when
tumours had reached a size of approximately 50mm3 the mice
were treated by injection of 50,ig FWP51 or FSP77/mouse/day
for a period of 10 days. Tumour growth was determined as in
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Figure 4 Effect of the monoclonal antibodies on the anchorage-
independent growth of NIH3T3#3.7 cells in soft-agar. Soft-agar
cultures with the indicated amounts of the antibodies were
prepared as described in Materials and methods. Colonies of
>0.2 mm size were counted after 21 days using an Artek
Counter. Each group shows the mean of triplicate samples and
the s.d. of the mean.
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(Hudziak et al., 1989; Stancovski et al., 1991; Harwerth et
al., 1992). It is likely that down-modulation results from the
ability of divalent antibodies to cross-link cell surface recep-
tors, which leads in turn to their internalisation.
The effect of the erbB-2 specific antibodies on the turnover
of the receptor in the NIH3T3#3.7, SKOV3 and SKBR3 cell
lines was examined. The SKBR3 cell line, which was previ-
ously studied (Harwerth et al., 1992), was reexamined in
order to look for the effect of a combinatorial treatment with
the two tumour-inhibitory MAbs. Cells were metabolically
labelled with [35S]methionine, then chased for 3 or 24 h in the
presence of individual antibodies or the FWP51/FSP77 com-
bination. The erbB-2 protein was immunoprecipitated and
analysed by SDS-PAGE. The results of the experiment are
shown in Figure 5. The turnover of the mutated erbB-2
receptor in NIH3T3#3.7 cells was more rapid than the
turnover of the normal receptor in the two tumour cell lines
reflecting the activated state of the mutated receptor (Barg-
mann & Weinberg, 1988; Yarden, 1990). Despite its rapid
turnover the binding of MAbs FRP5, FSP16 and FSP77
further increased the degradation of the erbB-2 receptor. The
extent of acceleration was cell line dependent with MAb
FSP77 being the most effective in NIH3T3#3.7 and SKOV3
cells. In all cell lines the binding of MAb FWP51 had little or
no effect. In NIH3T3#3.7 cells, combination treatment with
MAbs FWP51 and FSP77 induced a level of receptor turn-
over intermediate to that induced by single antibody treat-
ment (a). This observation correlates with the effect of the
MAb combination seen in the anchorage-independent growth
assay. In contrast FWP51 and FSP77 antibody combination
induced a more dramatic degradation of erbB-2 in the two
human cell lines than FSP77 treatment alone (b and c).
Discussion
The erbB-2 receptor is overexpressed in human tumours aris-
ing at various sites (Hynes, 1993 and ref. therein), including
breast, ovaries, lung, stomach and salivary gland. The acces-
sibility of this protein on the cell surface, and its implication
in the development and malignancy of these tumours, especi-
ally breast carcinomas (Slamon et al., 1989), make the erbB-2
receptor an attractive target for specific MAbs which may be
Figure 5 Turnover of the erbB-2 protein in intact cells following
binding of the specific antibodies. NIH3T3#3.7 (a), SKOV3 (b)
and SKBR3 cells (c) were labelled for 16 h with [35S] methionine,
then the label was removed and replaced by culture medium
containing either no additions (lane 3) or 101sgml-l of the
MAbs (lanes 4-8). After 3 h (a) and 24 h (b and c) of chase the
level of 35S-labelled erbB-2 protein was analysed as described in
Materials and methods. Equal amounts (counts per minute) of
35S-labelled lysate were immunoprecipitated in each group. The
control in lane 1 shows the radioactive erbB-2 protein at time 0.
Lane 2: cells chased in the absence of antibody and immuno-
precipitated with normal mouse serum. Lane 3: cells chased in the
absence of antibody and immunoprecipitated with a mixture of
the MAbs (a) or 21N (b and c). Lanes 4-8: cells chased with
MAbs FRP5, FSP16, FWP51, FSP77 and FWP51 + FSP77 and
immunoprecipitated with a mixture of the MAbs (a) or 21N (b
and c). The position of the erbB-2 protein is indicated.
useful in diagnosis and therapy. Several groups have raised
erbB-2-specific monoclonal antibodies (Hudziak et al., 1989;
McKenzie et al., 1989; Stancovski et al., 1991; Harwerth et
al., 1992). Results from immunohistochemical studies
indicate that embryonic tissues contain the highest level of
erbB-2 protein. In the adult expression is limited to certain
epithelial cells (Press et al., 1990). Therefore, monoclonal
antibodies directed against the erbB-2 protein may be
relatively specific in their targeting to tumours containing
elevated levels of the protein. We have previously described
the isolation and characterisation of four erbB-2 specific
MAbs which bind to the extracellular domain of the receptor
protein (Harwerth et al., 1992). In the present study we have
used two tumour models to address the potential of these
antibodies as anti-tumour agents. Furthermore, we attempted
to correlate the in vivo anti-tumour activities of the MAbs
with their effects on cultured tumour cells and on the recep-
tor itself.
The two tumour models tested were mouse fibroblasts
transformed by an activated human erbB-2 protein,
NIH3T3#3.7 cells, and human ovarian tumour cells,
SKOV3, which display c-erbB-2 gene amplification and
elevated levels of the erbB-2 protein. Activation of the erbB-2
receptor by a point mutation, as in the NIH3T3#3.7 cells, is
comparable to the situation of an overexpressed erbB-2
receptor. Peles et al. (1991) have shown that both modes of
oncogenic activation result in a constitutively phosphorylated
erbB-2 protein and in the phosphorylation of phospholipase1144 I.-M. HARWERTH et al.
CTy, a downstream substrate. NIH3T3#3.7 cells form rapidly
growing tumours in nude mice. Two of the four MAbs
tested, FWP51 and FSP77, completely inhibited the growth
of the tumours during the course of treatment and markedly
delayed the onset of tumour growth once treatment was
terminated. MAbs FWP51 and FSP77 also inhibited the
growth of established tumours, both those arising from
NIH3T3#3.7 cells (data not shown) and the SKOV3 tumour
implants. The different anti-tumour activities displayed by
the erbB-2 specific MAbs might be attributed to the binding
of the antibodies to different epitopes on the extracellular
domain of the receptor (Harwerth et al., 1992).
In an attempt to correlate the in vivo anti-tumour activity
of MAbs FWP51 and FSP77 to an in vitro measurable
activity, the effects of the MAbs on the anchorage-dependent
and -independent growth of erbB-2 expressing tumour cells
and on the erbB-2 receptor itself were characterised. A sum-
mary of these experiments, both those presented in this paper
and in a previous publication (Harwerth et al., 1992), is
shown in Table II. The most surprising result was the incon-
sistency between the effects which the MAbs had on growth
of tumours in nude mice and their effects upon the
anchorage-independent growth of NIH3T3#3.7 cells. Only
MAb FWP51 was inhibitory in both assays. The effects of
the MAbs on the monolayer growth of various cell lines was
also examined. These included NIH3T3#3.7 cells, SKBR3
and MDA-MB 453 breast tumour cells which express high
levels of erbB-2, MDA-MB 231 breast tumour cells with low
levels of erbB-2, and SKOV3 ovarian tumour cells with high
levels of erbB-2. SKBR3 cells were inhibited in their growth
by MAb FSP77 (Harwerth et al., 1992), the monolayer
growth of the other cell lines was not inhibited by treatment
with the four MAbs (data not shown). These results suggest
that the effects which the erbB-2 specific antibodies have
upon cell growth cannot be generalised, but are dependent
upon the assay and cell line examined. The monolayer
growth of erbB-2 transformed NIH3T3 fibroblasts is not
likely to be inhibited by antibody treatment since the
anchorage-dependent growth of these cells is not strictly
dependent upon activation of the erbB-2 receptor. The role
of the overexpressed erbB-2 receptor in the growth of
SKBR3 tumour cells is unclear. MAb FSP77 binding might
interfere with receptor activation. Some characteristics of
MAbs which contribute to their effects on tumour growth
may only be evident in animal experiments. These could
include serum half-life or tumour accessibility. Therefore con-
clusions drawn from in vitro experiments are likely to be of
minimal significance in predicting the anti-tumour activity of
an antibody.
Another unanticipated result was the fact that
NIH3T3#3.7 soft-agar colony number was stimulated more
than 10-fold by MAbs FRP5 and FSP16, the antibodies
which did not affect tumour growth in vivo. Following the
binding of MAbs FRP5 and FSP16 to cell lines expressing
the erbB-2 protein, an increase in the phosphotyrosine con-
tent of the receptor was observed (Harwerth et al., 1992).
These results suggested that the antibodies might be ligand
agonists and stimulate the growth of some erbB-2 expressing
cells. We analysed this by measuring the effects of MAb
treatment on DNA synthesis. Neither treatment of
NIH3T3#3.7 cells, nor of any other erbB-2 expressing cell
line, with MAb FRP5 or FSP16 led to a measurable increase
in DNA synthesis (Harwerth et al., 1992 and data not
shown). These results, together with the fact that MAbs
FRP5 and FSP16 did not stimulate the soft-agar growth of
SKOV3 cells, and had no stimulatory effect upon monolayer growth of NIH3T3#3.7 cells and other tested cell lines (data
not shown), suggest that the data obtained in the soft-agar colony assay reflect a peculiarity of the anchorage- independent growth of the NIH3T3#3.7 cells expressing an
activated erbB-2 receptor.
With respect to the down-regulation of the erbB-2 recep-
tor, MAb FSP77 generally was most potent in stimulating its
turnover (Table IIand Harwerth et al., 1992). It is tempting
to argue that the loss of receptors from the cell surface may
Table II
Effects of FWP51
erbB-2 spec. +
MAbs on: FRP5 FSP16 FWP5J FSP77 FSP77
Growth
Tumour growth:
NIH3T3#3.7 none none - - --
SKOV3 n.d.a n.d. - - n.d.
Cell growth
(anchorage-independent):
NIH3T3#3.7 +++ +++ + b
Receptor
Turnover:
NIH3T3#3.7 ++ ++ + +++ ++
SKOV3 + ++ + +++ ++++
SKBR3 ++ ++ + ++ +++
aNot determined; bdose dependent.
result in the in vivo inhibition of tumour growth, an effect
which has been reported for a neu specific MAb (Drebin et
al., 1985) and a combination of erbB-2 specific MAbs (Kas-
przyk et al., 1992). Conversely, MAb FWP51 on its own had
little effect on receptor turnover (Table II and Harwerth et
al., 1992), but was very potent in inhibiting tumour growth.
In the two human tumour cell lines, SKBR3 and SKOV3, the
combined treatinent with MAbs FWP51 and FSP77 led to a
dramatic increase in receptor turnover. We have observed
that the overall level of erbB-2 protein remaining in SKBR3
cells following 2 day treatment with MAbs FWP51 and
FSP77, and with a combination of the two, was reduced by,
respectively 15, 40 and 45% (data not shown). These results
suggest that in the mice long-term treatment with MAb
FWP51 may indeed lead to a reduction in the tumour erbB-2
level, which was not measurable in the labelling experiment
presented in Figure 5. From these results we favour the idea
that the combination of epitopes recognised by MAbs
FWP51 and FSP77, and the reduction in the overall level of
the erbB-2 protein both contribute to the anti-tumour activity
of these antibodies.
The results show that treatment with anti-erbB-2
antibodies which bind to different domains of the receptor
leads to potent in vivo anti-tumour effects. However, tumour
growth inhibition by the antibodies was transitory. Once
treatment was discontinued the tumours regrew. Therefore a
more successful approach will likely involve the combination
of a specific antibody with a potent effector function. erbB-2
specific MAbs, which were expressed as recombinant single
chain antibody-toxin chimeric molecules (Wels et al., 1992b;
Batra et al., 1992), displayed cytotoxic anti-tumour activity.
Short-term treatment with a low dose of scFv(FRP5)-ETA
inhibited SKOV3 tumour cell growth by 96% (Wels et al.,
1992b) and NIH3T3#3.7 tumour growth by 80% (this pub-
lication). Since MAb FRP5 had no anti-tumour activity on
its own, more dramatic results might be achieved when one
of the inhibitory antibodies is coupled with a toxic agent. In
this configuration all four monoclonal antibodies might have
a potential as therapeutic agents in the treatment of human
malignancies.
We thank Drs U. Regenass and B. Groner for their helpful discus-
sions and Dr D. Taverna and B. Marte for their suggestions on the
manuscript.
Abbreviations: MAb, monoclonal antibody; EGF, epidermal growth
factor; DMEM, Dulbecco's modified Eagle's medium; FCS, foetal
calf serum; ELISA, enzyme-linked immunosorbent assay; ETA,
exotoxin A; PBS, phosphate buffered saline; SDS-PAGE, sodium
dodecylsulfate-polyacrylamide gel electrophoresis; IgG, immuno-
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